Asia · Regional markets · Pulse (Maeil Business)

Samsung Bioepis signs $420 mn U.S. biosimilar deal with Teva

Published by Pulse (Maeil Business) · South Korea 9 h ago

Samsung Bioepis has signed a U.S. commercialization agreement worth up to $420 million with global pharmaceutical company Teva, expanding its presence in the world’s largest…

Read the full article on Pulse (Maeil Business) Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (pulse.mk.co.kr)

Also worth reading

Mint

539% return in 5 years: GMDC share price rallies 10% - What’s fuelling the PSU stock rally? Decoded

Business Standard

New Samvat brings opportunities in mutual funds, equities and gold: Experts

CNBC-TV18

Chalet Hotels Q2 results: Net profit rises 39.7% to ₹216.2 crore; revenue falls 31.7%

Tech in Asia

SG AI startup Featherless to add MiniMax M3.1 Flash for coding

The Straits Times Business

McDonald’s US sales decline for first time in six quarters despite value push

The Business Times